As all of these examples have been identified in breast cancer, it will be important to understand their prevalence in other disease settings and the clinical relevance of mutations in components of the 53BP1–Shieldin complex other than 53BP1 itself. This evidence concerns the gene TP53BP1 and breast carcinoma.